A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.

Inexpensive, simple, rapid diagnostics are necessary for efficient detection, treatment, and mitigation of COVID-19. Assays for SARS-CoV2 using reverse transcription polymerase chain reaction (RT-PCR) offer good sensitivity and excellent specificity, but are expensive, slowed by transport to central...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benjamin D Grant, Caitlin E Anderson, Luis F Alonzo, Spencer H Garing, John R Williford, Ted A Baughman, Rafael Rivera, Veronika A Glukhova, David S Boyle, Puneet K Dewan, Bernhard H Weigl, Kevin P Nichols
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ad82acb0f6cd47f087c370ee780bc055
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad82acb0f6cd47f087c370ee780bc055
record_format	dspace
spelling	oai:doaj.org-article:ad82acb0f6cd47f087c370ee780bc0552021-12-02T20:16:23ZA SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.1932-620310.1371/journal.pone.0258819https://doaj.org/article/ad82acb0f6cd47f087c370ee780bc0552021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0258819https://doaj.org/toc/1932-6203Inexpensive, simple, rapid diagnostics are necessary for efficient detection, treatment, and mitigation of COVID-19. Assays for SARS-CoV2 using reverse transcription polymerase chain reaction (RT-PCR) offer good sensitivity and excellent specificity, but are expensive, slowed by transport to centralized testing laboratories, and often unavailable. Antigen-based assays are inexpensive and can be rapidly mass-produced and deployed at point-of-care, with lateral flow assays (LFAs) being the most common format. While various manufacturers have produced commercially available SARS-Cov2 antigen LFAs, access to validated tests remains difficult or cost prohibitive in low-and middle-income countries. Herein, we present a visually read open-access LFA (OA-LFA) using commercially-available antibodies and materials for the detection of SARS-CoV-2. The LFA yielded a Limit of Detection (LOD) of 4 TCID50/swab of gamma irradiated SARS-CoV-2 virus, meeting the acceptable analytical sensitivity outlined by in World Health Organization target product profile. The open-source architecture presented in this manuscript provides a template for manufacturers around the globe to rapidly design a SARS-CoV2 antigen test.Benjamin D GrantCaitlin E AndersonLuis F AlonzoSpencer H GaringJohn R WillifordTed A BaughmanRafael RiveraVeronika A GlukhovaDavid S BoylePuneet K DewanBernhard H WeiglKevin P NicholsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0258819 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Benjamin D Grant Caitlin E Anderson Luis F Alonzo Spencer H Garing John R Williford Ted A Baughman Rafael Rivera Veronika A Glukhova David S Boyle Puneet K Dewan Bernhard H Weigl Kevin P Nichols A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.
description	Inexpensive, simple, rapid diagnostics are necessary for efficient detection, treatment, and mitigation of COVID-19. Assays for SARS-CoV2 using reverse transcription polymerase chain reaction (RT-PCR) offer good sensitivity and excellent specificity, but are expensive, slowed by transport to centralized testing laboratories, and often unavailable. Antigen-based assays are inexpensive and can be rapidly mass-produced and deployed at point-of-care, with lateral flow assays (LFAs) being the most common format. While various manufacturers have produced commercially available SARS-Cov2 antigen LFAs, access to validated tests remains difficult or cost prohibitive in low-and middle-income countries. Herein, we present a visually read open-access LFA (OA-LFA) using commercially-available antibodies and materials for the detection of SARS-CoV-2. The LFA yielded a Limit of Detection (LOD) of 4 TCID50/swab of gamma irradiated SARS-CoV-2 virus, meeting the acceptable analytical sensitivity outlined by in World Health Organization target product profile. The open-source architecture presented in this manuscript provides a template for manufacturers around the globe to rapidly design a SARS-CoV2 antigen test.
format	article
author	Benjamin D Grant Caitlin E Anderson Luis F Alonzo Spencer H Garing John R Williford Ted A Baughman Rafael Rivera Veronika A Glukhova David S Boyle Puneet K Dewan Bernhard H Weigl Kevin P Nichols
author_facet	Benjamin D Grant Caitlin E Anderson Luis F Alonzo Spencer H Garing John R Williford Ted A Baughman Rafael Rivera Veronika A Glukhova David S Boyle Puneet K Dewan Bernhard H Weigl Kevin P Nichols
author_sort	Benjamin D Grant
title	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.
title_short	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.
title_full	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.
title_fullStr	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.
title_full_unstemmed	A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.
title_sort	sars-cov-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/ad82acb0f6cd47f087c370ee780bc055
work_keys_str_mv	AT benjamindgrant asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT caitlineanderson asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT luisfalonzo asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT spencerhgaring asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT johnrwilliford asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT tedabaughman asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT rafaelrivera asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT veronikaaglukhova asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT davidsboyle asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT puneetkdewan asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT bernhardhweigl asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT kevinpnichols asarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT benjamindgrant sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT caitlineanderson sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT luisfalonzo sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT spencerhgaring sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT johnrwilliford sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT tedabaughman sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT rafaelrivera sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT veronikaaglukhova sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT davidsboyle sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT puneetkdewan sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT bernhardhweigl sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay AT kevinpnichols sarscov2coronavirusnucleocapsidproteinantigendetectinglateralflowassay
_version_	1718374488103452672

A SARS-CoV-2 coronavirus nucleocapsid protein antigen-detecting lateral flow assay.

Ejemplares similares